Elixir Medical Announces Outstanding Two-Year Results From the EXCELLA BD Randomized Clinical Trial for the CE Mark-Approved DESyne® BD System With Biodegradable Polymer Coating
5/24/2013 10:14:22 AM
More...
|
Elixir Medical Announces Excellent Six-Month Safety and Efficacy Results for the CE-Marked Fully Bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System at Late Breaking Clinical Trial Session of EuroPCR
5/21/2013 10:47:07 AM
More...
|
Elixir Medical's DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System CE Marked
5/15/2013 7:21:22 AM
More...
|
Elixir Medical Goes Head-to-Head Against Medtronic, Inc. (MDT) With Its DESyne Nx DES Study
5/14/2013 9:01:08 AM
More...
|
Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting Coronary Stent System in the United States
5/8/2013 11:06:04 AM
More...
|
Elixir Medical to Present at J.P. Morgan Healthcare Conference
12/21/2012 6:25:42 AM
More...
|
Elixir Medical Announces Schedule of Programs for TCT 2012
10/17/2012 9:33:51 AM
More...
|
Elixir Medical Receives CE Mark Approval for the DESyne® BD Novolimus Eluting Coronary Stent System With Biodegradable Polymer Coating
8/28/2012 8:03:52 AM
More...
|
Elixir Medical Announces Excellent Results from DESolve I First-In-Man Study for the Fully Bioresorbable Drug Eluting Coronary Scaffold System
5/16/2012 10:54:53 AM
More...
|
Elixir Medical Announces Continued Excellent One Year Safety and Efficacy Data from the EXCELLA BD Randomized Clinical Trial for DESyne BD™ Novolimus Eluting Coronary Stent with Biodegradable Polymer
5/15/2012 10:42:21 AM
More...
|
|